We are extremely proud and honored to announce that Chinese Clinical Oncology (CCO, Figure 1) is now indexed by MEDLINE database and all articles published in CCO will be searchable in PubMed after the inclusion of MEDLINE, the primary component of PubMed. Not only is this a significant milestone for CCO as an acknowledgment of its influence and dedication to oncology cancer, but also will tremendously advance its continued exploration and further enhance the academic significance in the field.
Figure 1 The sample of Chinese Clinical Oncology (CCO)
Launched quarterly in September 2012, CCO publishes articles that describe new findings in the field of oncology, provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. CCO is officially endorsed by Chinese Society of Clinical Oncology (CSCO).
Till now, ten issues of CCO have been published, among which four are focused issues (Table 1). The focused issues that were guest-edited by the leading experts in their field highlight the updated research in a specific field, providing a critical analysis and comprehensive overview of contemporary and at times controversial aspects of the topic. It is expected that these focused issues will allow tremendous progress in our ongoing understanding and sharing of knowledge. The amount of submissions published has increased steadily over the 3 years (Figure 2).
Figure 2 The amount of submissions published in CCO from 2012 to 2014
CCO attaches great importance to providing a platform for discussion and experience sharing of clinical oncology research. The special column “Statistics in Oncology Clinical Trials” in CCO chaired by Prof. Daniel J. Sargent and Prof. Qian Shi from Mayo Clinic has been published in three issues and will be run continuously (www.thecco.net/post/view/statistics-in-oncology-clinical-trials).
Also, more focused issues are coming. The potential topics are listed at Table 2. Among them, the issue on “Clinical Trials in the Genome Era—Study Designs and Endpoints, Practical Considerations” will include overview papers on general statistical and clinical issues, papers highlighting challenges within specific disease types, as well as profiles of selected genome-based trials. The issue on “Lung Cancer” edited by Dr. Jean-pierre Armand and Dr. Ju Liya will feature presentations given in Sino-French 2014 Symposium in Thoracic Oncology to reflect the collaborative effort and the cutting-edge technology and research cooperation between China and France and has become part of the 50th anniversary of the Sino-French collaboration.
As stated by prof. Charles M. Balch, the Editor-in-Chief in Annals of Surgical Oncology “It is a large and competitive arena for high quality publications. Nevertheless, I am confident that CCO will provide another venue for high quality publications based upon the impressive expansive of research activities in China and will attract excellent publications from investigators in China, elsewhere in Asia, and throughout the world”, we believe this valuable inclusion by MEDLINE will widely promote the dissemination of articles published in our journal to all over the world, eventually benefiting the oncologists’ clinical practices and scientific research and health care for patients.
We deeply thank the distinguished Editors-in-Chief and editorial board members, respectable authors and readers worldwide for their lasting support and contribution.
Thanks to their joint efforts, CCO is successfully indexed by MEDLINE now. With more confidence and expectation, CCO will continue to work towards a robust platform with increased impact for the education, communication and exploration of the international researchers and clinicians.